{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T12:51:23Z","timestamp":1693745483095},"reference-count":7,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1136\/archdischild-2018-315819","type":"journal-article","created":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T16:16:48Z","timestamp":1538065008000},"page":"212-213","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Biological therapeutic drug monitoring: a step towards precision medicine?"],"prefix":"10.1136","volume":"104","author":[{"given":"William D","family":"Renton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athimalaipet V","family":"Ramanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,9,27]]},"reference":[{"key":"2020050712483230000_104.3.212.1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/aps.2012.51","article-title":"Clinical pharmacology considerations in biologics development","volume":"33","author":"Zhao","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"2020050712483230000_104.3.212.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204172"},{"key":"2020050712483230000_104.3.212.3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MEG.0000000000000544","article-title":"Comparative analysis of the influence of clinical factors including BMI on adalimumab and infliximab trough levels","volume":"28","author":"Bond","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2020050712483230000_104.3.212.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135111"},{"key":"2020050712483230000_104.3.212.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211781"},{"key":"2020050712483230000_104.3.212.6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/archdischild-2018-315100","article-title":"Utility of proactive infliximab levels in paediatric Crohn\u2019s disease","volume":"104","author":"Burgess","year":"2019","journal-title":"Arch Dis Child"},{"key":"2020050712483230000_104.3.212.7","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-316813"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2018-315819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T22:14:34Z","timestamp":1601072074000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2018-315819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,27]]},"references-count":7,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,19]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1136\/archdischild-2018-315819"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2018-315819","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,27]]}}}